Rate Video

BTOG 2022 Summer Meeting | Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?

Riyaz Shah • 8 Jul 2022

BTOG 2022 Summer Meeting

Lung Cancer Mesothelioma

Immuno-Oncology

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses which subsets of patients with mesothelioma benefit from immunotherapy. This interview took place at the BTOG 2022 Summer Meeting congress in London.

Management of frontline ALK+ NSCLC: brigatinib vs. alectinib

Riyaz Shah • 29 Jan 2020

Improving immunotherapy outcomes in mesothelioma

Riyaz Shah • 8 Jul 2022

Impacts of COVID-19 on lung cancer diagnosis in the UK

Riyaz Shah • 23 Apr 2021

UK excels at molecular testing for lung cancer

Riyaz Shah • 29 Jan 2020

Related Videos

Building a clinical research platform to capture and leverage data from cancer care in Germany

Frank Griesinger

Improving responses to immunotherapy in NSCLC

How to discuss immunotherapy as a treatment option with lung cancer patients

Clinical factors in the selection of patients for first-line immunotherapy of lung cancer